Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | MAOA | P21397 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | PPOX | P50336 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11436726 | 0.89 | MAPT (0.48) | NPC1MAOAMAPTALDH1A1KDM4E | |
| SCHEMBL11652672 | 0.88 | MAPT (0.52) | NPC1MAOAMAPTALDH1A1KDM4E | |
| SCHEMBL10653562 | 0.84 | NPC1 (0.57) | NPC1MAOAMAPTALDH1A1KDM4E | |
| SCHEMBL12759053 | 0.84 | NPC1 (0.47) | NPC1MAPTALDH1A1KDM4EHSD17B10 | |
| SCHEMBL13254972 | 0.84 | KDM4E (0.46) | NPC1MAPTALDH1A1KDM4EHSD17B10 | |
| SCHEMBL6371564 | 0.83 | GAA (0.55) | NPC1MAPTALDH1A1KDM4EHSD17B10 | |
| SCHEMBL12161176 | 0.82 | MAOA (0.56) | NPC1MAOAALDH1A1L3MBTL1CYP1A2 | |
| SCHEMBL27304096 | 0.82 | NPC1 (0.46) | NPC1MAOAMAPTALDH1A1KDM4E | |
| SCHEMBL8599602 | 0.82 | PPOX (0.45) | NPC1MAOAMAPTALDH1A1KDM4E | |
| SCHEMBL12299454 | 0.82 | LMNA (0.52) | MAPTALDH1A1KDM4EL3MBTL1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4402132-A1 | FABP4/5 INHIBITORS, METHODS OF USE AND METHODS OF MAKING | Celloram, Inc. (US) | 2024-07-24 | — | — | EP | claimed |
| CN-118103357-A | FABP4/5 inhibitors, methods of use and methods of preparation | 塞洛拉姆股份有限公司 | 2024-05-28 | — | — | CN | claimed |
| WO-2023043803-A1 | FABP4/5 INHIBITORS, METHODS OF USE AND METHODS OF MAKING | NOVIUS THERAPEUTICS, LLC (US) | 2023-03-23 | — | — | WO | claimed |
| US-20260132106-A1 | FABP4/5 INHIBITORS, METHODS OF USE AND METHODS OF MAKING | CELLORAM, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| US-12570603-B2 | FABP4/5 inhibitors, methods of use and methods of making | CELLORAM INC. (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4402132-A1 | FABP4/5 INHIBITORS, METHODS OF USE AND METHODS OF MAKING | Celloram, Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| CN-118103357-A | FABP4/5 inhibitors, methods of use and methods of preparation | 塞洛拉姆股份有限公司 | 2024-05-28 | — | — | CN | disclosed |
| US-20230150931-A1 | FABP4/5 INHIBITORS, METHODS OF USE AND METHODS OF MAKING | NOVIUS THERAPEUTICS, LLC (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230150931-A1 | FABP4/5 INHIBITORS, METHODS OF USE AND METHODS OF MAKING | NOVIUS THERAPEUTICS, LLC (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230150931-A1 | FABP4/5 INHIBITORS, METHODS OF USE AND METHODS OF MAKING | NOVIUS THERAPEUTICS, LLC (US) | 2023-05-18 | — | — | US | disclosed |
| WO-2023043803-A1 | FABP4/5 INHIBITORS, METHODS OF USE AND METHODS OF MAKING | NOVIUS THERAPEUTICS, LLC (US) | 2023-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12570603-B2 | FABP4/5 inhibitors, methods of use and methods of making | FABP5, FABP1, FABP4 | NPC1 130/4885MAOA 4762/4885MAPT 3029/4885 |
| US-20260132106-A1 | FABP4/5 INHIBITORS, METHODS OF USE AND METHODS OF MAKING | FABP5, FABP4, FABP1 | NPC1 206/4885MAOA 4124/4885MAPT 3515/4885 |
| US-20230150931-A1 | FABP4/5 INHIBITORS, METHODS OF USE AND METHODS OF MAKING | FABP5, FABP1, FABP4 | NPC1 268/4885MAOA 2622/4885MAPT 3579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.